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ACE–PrEvEntion PAmPhlEts  
PAmPhlEt A: thE ACE–PrEvEntion ProjECt
1. IntroductIon
Governments across the world are faced with rising health care costs due to the ageing of the population, greater 
demands for health services and, in particular, the introduction of new expensive technologies. As a consequence, 
governments, as the main providers of health services, are under increasing pressure to justify their resource allocation 
decisions.  The current global economic recession makes careful and rational allocation of health resources an even 
greater imperative.  In such an environment, reliable, objective evidence on the causes of and trends in disease burden 
and health expenditure, and on the costs and likely effectiveness of interventions to reduce these, is a key input into 
health policy decision-making.  Without such evidence, policies and programs to improve health are unlikely to achieve 
their potential for maximising population health levels. 
 
To aid priority setting in prevention, the Assessing Cost-Effectiveness in Prevention Project (ACE-Prevention) applies 
standardised evaluation methods to assess the cost-effectiveness of 100 to 150 preventive interventions, taking a 
health sector perspective. This information is intended to help decision-makers move resources from less efficient 
current practices to more efficient preventive action resulting in greater health gain for the same outlay. 
 
This briefing paper is the first of several designed to communicate the methods and results of the ACE-Prevention 
project. In this paper, the disease burden in Australia, the associated health expenditure and the aims of the ACE-
Prevention Project are briefly overviewed. 
 
2. australIa’s health
Australia’s health compares well with that of other countries. It has the second highest life expectancy, with males 
ranking fourth best and females ranking third best in the world. Also, when taking ‘healthy life’ and not just length 
of life into account, Australia ranked fifth highest in the world in 2004. While there are some differences in these 
indicators between states, between urban and rural areas, Indigenous Australians experience by far the worst health 
in the country. For 2003, the gap in life expectancy between Indigenous Australians and the total population was 
estimated to be 13 years, but ranging from 11 years for Indigenous Australians living in towns and cities, to 18 years for 
Indigenous Australians living in remote areas. The most recent estimate of the Australian Bureau of Statistics is a gap 
of 11 years in life expectancy. This is less than their previous estimate of a 17 year gap, but reflects improved methods 
rather than a real change. 
The Australian Burden of Disease study provides a wealth of information on the diseases (Table 1) and risk factors 
(Figure 1) that contribute most to the total loss of health in the country.
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We also know what diseases and what risk factors contribute most to the Indigenous health gap (Figures 2 and 3).
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The Australian Burden of Disease study provides a wealth of information on the 
diseases (Table 1) and risk factors (Figure 1) that contribute most to the total loss of 
health in the country. 
Table 1. Leading causes of burden by sex, Australia 2003 
 
Rank Males DALYs % of 
total 
  Females DALYs % of 
total 
1 Ischaemic heart disease  151,107  11.0   Anxiety & depression  126,455  10.0 
2 Type 2 diabetes  76,886  5.6   Ischaemic heart disease  112,385  8.9 
3 Anxiety & depression  65,323  4.8   Stroke  65,166  5.2 
4 Lung cancer  55,028  4.0   Dementia  60,734  4.8 
5 Stroke  53,296  3.9   Breast cancer  60,517  4.8 
6 Chronic obstructive 
pulmonary disease 
 49,201  3.6   Type 2 diabetes  55,737  4.4 
7 Adult-onset hearing loss  42,653  3.1   Chronic obstructive 
pulmonary disease 
 37,548  3.0 
8 Suicide  38,717  2.8   Lung cancer  33,876  2.7 
9 Prostate cancer  36,547  2.7   Asthma  33,827  2.7 
10 Colorectal cancer  34,643  2.5   Colorectal cancer  28,961  2.3 
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3. Health expenditure 
A projection of year 2002-03 disease burden and associated health expenditure to 2033 
shows a large increase in health expenditure, particularly for diabetes and the chronic 
degenerative diseases in old age for which there are inadequate prevention or treatment 
interventions (Table 2). 
 
4. Aims of ACE-Prevention project 
Information on the size of health problems and associated expenditure alone is not 
enough to set priorities. A health problem may be large, but if no means of prevention or 
alleviation of disability exists, it is not a health service priority but more a priority for 
health research. Conversely, a small size of burden for another health problem does not 
mean that health expenditure for that disease can be reduced. It may well be that the 
current investment is the reason for the small size of the remaining disease burden. 
Priority setting requires additional analyses on the costs and outcomes of current health 
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servic  inte v ntions and alternative approaches to reducing th  health burden. 
Economics is the discipline that helps to guide such decision-making. 
Table 2. Projected total health expenditure (2002–03 dollars) by cause, Australia, 2002–03 to 
2032–33 
 Expenditure by year ($billion) Change 2003-2033 
Cause 2002–03 2032–33 Per cent 
Cardiovascular 9.3 22.6 143% 
Respiratory 7.2 22.0 206% 
Injuries 6.7 14.4 115% 
Dental 5.9 14.9 153% 
Mental 5.2 12.1 133% 
Digestive 4.9 16.5 237% 
Neurological 4.7 21.5 357% 
Musculoskeletal 4.4 14.2 223% 
Genitourinary 3.7 10.9 195% 
Cancer 3.5 10.1 189% 
Diabetes 1.6 8.6 438% 
Other (b) 28 78.3 180% 
Total health expenditure 85.1 246.1 189% 
 
Over the last 10 years, Rob Carter from Deakin University and Theo Vos from the 
University of Queensland, have developed a systematic approach to economic 
evaluation of health interventions in Australia. This has included studies on cancer 
prevention, heart disease, mental disorders and obesity prevention in children and 
adolescents. All these studies have been labeled ACE – “topic area” with ACE standing 
for Assessing Cost-Effectiveness. The largest ACE study is ACE-Prevention. It received 
NHMRC funding for the period 2005-2009. The study has a broad focus on prevention 
and non-communicable disease and evaluates the policy implications for the population 
as a whole and for Indigenous Australians separately. This is because the target disease 
burden, the prevalence and distribution of harmful exposures, the effectiveness of 
intervention strategies, and the cost of implementing effective interventions is likely to 
differ substantially between Indigenous and non-Indigenous Australians. 
Each economic evaluation undertaken as part of ACE-Prevention complies with the 
standardised evaluation methods set out to ensure comparability of cost-effectiveness 
results. The final output of the study is a league table of the cost-effectiveness of these 
preventive interventions compared to a selected, smaller number of curative and 
infectious disease control interventions ranked in order of their economic merit. Within 
topic areas (e.g. diabetes prevention or reduction of the harm from alcohol) 
combinations of interventions are analysed to determine the most cost-effective package 
of interventions to address that particular health problem. 
The ultimate goal of this information is to help decision-makers move resources towards 
more efficient options by new investments in proven cost-effective packages of 
interventions or by shifting funds from less efficient current practices to more efficient 
preventive action. Careful scrutiny of the available evidence for each intervention also 
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disease control interventions ranked in order of their economic merit. Within topic areas (e.g. diabetes prevention or 
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The ultimate goal of this information is to help decision-makers move resources towards more efficient options by new 
investments in proven cost-effective packages of interventions or by shifting funds from less efficient current practices 
to more efficient preventive action. Careful scrutiny of the available evidence for each intervention also allows us to 
make recommendations for key areas of research to improve the evidence base. 
 
For more information, please visit:  www.sph.uq.edu.au/bodce-ace-prevention
 
 
 
 
indigenous population results 
1.   Cardiovascular disease prevention 
2.   Diabetes prevention 
3.   Screening and early treatment of chronic kidney disease
overall results 
1.   League table 
2.   Combined effects 
General population results 
1.    Adult depression 
2.    Alcohol 
3.    Blood pressure and cholesterol lowering 
4.    Cannabis 
5.    Cervical cancer screening, Sunsmart and PSA screening 
6.    Childhood mental disorders 
7.    Fruit and vegetables 
8.    HIV 
9.    Obesity 
10.  Osteoporosis 
11.   Physical activity 
12.   Pre diabetes screening 
13.   Psychosis 
14.    Renal replacement therapy, screening and  
early treatment of chronic kidney disease
15.   Salt 
16.   Suicide prevention 
17.   Tobacco 
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